1 Introduction to the Presentations
M.A. Lewis
From 27 to 29 August 2003, a group of scientists, all leaders in their field, met to discuss the status of hormone replacement therapy (HRT) follow- ing the results of recent epidemiological studies which had surprisingly indicated the presence of cardiovascular and in particular breast cancer risks associated with HRT. The meeting was convened in the picturesque setting of the Andechs cloister in Bavaria. Its purpose was to discuss all aspects of HRT use independent of pharmaceutical manufacturers and to provide a state-of-the-art assessment of the issues related to HRT risks.
The workshop was organised in such a way as to provide a forum for
all features of hormone replacement therapy, some of which went be-
yond the specific issue and addressed issues related to drug treatment in
general. Thus the contributions to the workshop included presentations
of such general import as the definition of the term “responsibility” for
both of the manufacturer of medicines and the prescriber (see Profes-
sor Poser’s paper), risk perception and risk communication (Heilmann),
as well as the historical (Teichmann) and practical (Schneider) aspects
of HRT use and prescription. Epidemiological results and issues were
addressed by Heinemann, Lidegaard, and Shapiro. The specific areas
of concern, i.e. those disease entities for which association was found
among HRT users, such as endometrial cancer (Horn), colon cancer and
ovarian cancer (Dietel), breast cancer (Böcker), and cardiovascular dis-
ease (Windler), were independently addressed. The list of participants
4 M.A. Lewis